Last reviewed · How we verify
Decadron-La (DEXAMETHASONE ACETATE)
Decadron-La (Dexamethasone Acetate) is a corticosteroid medication developed by Merck, targeting the glucocorticoid receptor. It is used to treat multiple myeloma and is classified as a small molecule modality. As an off-patent medication, it is available from generic manufacturers. Decadron-La is a commercial product with a long history of FDA approval since 1973. Its commercial status and availability make it a viable treatment option for patients.
At a glance
| Generic name | DEXAMETHASONE ACETATE |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
- Multiple myeloma
Common side effects
Key clinical trials
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 10028965 | 2034-05-23 | Method of Use |
| 8563027 | 2030-02-12 | Method of Use |
| 12144889 | 2041-04-26 | Method of Use |
| 12150896 | 2036-10-07 | Method of Use |
| 11097061 | 2039-06-23 | Formulation |
| 10022502 | 2034-06-22 | Method of Use |
| 11458041 | 2037-11-16 | Method of Use |
| 11304961 | 2037-12-18 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Decadron-La CI brief — competitive landscape report
- Decadron-La updates RSS · CI watch RSS
- Merck & Co. portfolio CI